Onconetix, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $815.4K | $2.5M | $58.5K |
| Cost of Revenue | $182.5K | $1.5M | $1.2M |
| Gross Profit | $632.9K | $1.1M | $-1.1M |
| Gross Margin | 77.6% | 41.8% | -1,927.9% |
| Operating Expenses | |||
| Research & Development | — | $154.4K | $1.9M |
| SG&A Expense | $7.0M | $11.2M | $14.8M |
| Operating Income | $-17.9M | $-56.5M | $-36.0M |
| Operating Margin | -2,190.0% | -2,238.0% | -61,634.5% |
| Interest Expense | — | — | $671.6K |
| Pretax Income | $-14.0M | $-59.7M | $-37.4M |
| Income Tax Expense | $525 | $-1.0M | $-12.6K |
| Net Income | $-14.0M | $-58.7M | $-37.4M |
| Net Margin | -1,721.0% | -2,325.2% | -63,986.5% |
| EPS (Basic) | $-16.56 | $-1,823.39 | $-3.02 |
| EPS (Diluted) | $-16.56 | $-1,823.39 | $-3.02 |
| Shares Outstanding (Basic) | 937.7K | 32.3K | 12.4M |
| Shares Outstanding (Diluted) | 937.7K | 32.3K | 12.4M |
| Dividends Per Share | — | — | — |